BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 20627233)

  • 1. [Cowden syndrome, or multiple hamartomatous tumor syndrome, in clinical endocrinology].
    Sardinoux M; Raingeard I; Bessis D; Coupier I; Renard E; Bringer J
    Ann Endocrinol (Paris); 2010 Sep; 71(4):264-73. PubMed ID: 20627233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTEN hamartoma tumor syndromes.
    Blumenthal GM; Dennis PA
    Eur J Hum Genet; 2008 Nov; 16(11):1289-300. PubMed ID: 18781191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTEN hamartomatous tumor syndromes (PHTS): rare syndromes with great relevance to common cancers and targeted drug development.
    Lopiccolo J; Ballas MS; Dennis PA
    Crit Rev Oncol Hematol; 2007 Sep; 63(3):203-14. PubMed ID: 17643312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cowden syndrome: report of two cases with immunohistochemical analysis for PTEN expression.
    Zabetian S; Mehregan D
    Am J Dermatopathol; 2012 Aug; 34(6):632-4. PubMed ID: 22481496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pten loss in the mouse thyroid causes goiter and follicular adenomas: insights into thyroid function and Cowden disease pathogenesis.
    Yeager N; Klein-Szanto A; Kimura S; Di Cristofano A
    Cancer Res; 2007 Feb; 67(3):959-66. PubMed ID: 17283127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Male breast cancer in Cowden syndrome patients with germline PTEN mutations.
    Fackenthal JD; Marsh DJ; Richardson AL; Cummings SA; Eng C; Robinson BG; Olopade OI
    J Med Genet; 2001 Mar; 38(3):159-64. PubMed ID: 11238682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilizing PTEN immunohistochemistry as a screening test for Cowden syndrome.
    Hartsough E; DeSimone MS; Lorenzo ME; Dias-Santagata D; Nose V; Hoang MP
    Am J Clin Pathol; 2024 May; 161(5):490-500. PubMed ID: 38206110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features.
    Pilarski R; Stephens JA; Noss R; Fisher JL; Prior TW
    J Med Genet; 2011 Aug; 48(8):505-12. PubMed ID: 21659347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
    Slomovitz BM; Coleman RL
    Clin Cancer Res; 2012 Nov; 18(21):5856-64. PubMed ID: 23082003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical staining of thyroidectomy specimens for PTEN can aid in the identification of patients with Cowden syndrome.
    Barletta JA; Bellizzi AM; Hornick JL
    Am J Surg Pathol; 2011 Oct; 35(10):1505-11. PubMed ID: 21921783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cowden syndrome presenting with trichilemmomas.
    Ng E; Terushkin V; Meehan SA; Ho R; Pomeranz MK
    Dermatol Online J; 2016 Dec; 22(12):. PubMed ID: 28329541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hamartoma-like lesions in the mouse retina: an animal model of
    Tachibana N; Touahri Y; Dixit R; David LA; Adnani L; Cantrup R; Aavani T; Wong RO; Logan C; Kurek KC; Schuurmans C
    Dis Model Mech; 2018 May; 11(5):. PubMed ID: 29716894
    [No Abstract]   [Full Text] [Related]  

  • 13. PTEN lipid phosphatase activity and proper subcellular localization are necessary and sufficient for down-regulating AKT phosphorylation in the nucleus in Cowden syndrome.
    He X; Saji M; Radhakrishnan D; Romigh T; Ngeow J; Yu Q; Wang Y; Ringel MD; Eng C
    J Clin Endocrinol Metab; 2012 Nov; 97(11):E2179-87. PubMed ID: 22962422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria.
    Pilarski R; Burt R; Kohlman W; Pho L; Shannon KM; Swisher E
    J Natl Cancer Inst; 2013 Nov; 105(21):1607-16. PubMed ID: 24136893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term treatment of cancer-prone germline PTEN mutant mice with low-dose rapamycin extends lifespan and delays tumour development.
    Tibarewal P; Rathbone V; Constantinou G; Pearce W; Adil M; Varyova Z; Folkes L; Hampson A; Classen GAE; Alves A; Carvalho S; Scudamore CL; Vanhaesebroeck B
    J Pathol; 2022 Dec; 258(4):382-394. PubMed ID: 36073856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes.
    Orloff MS; He X; Peterson C; Chen F; Chen JL; Mester JL; Eng C
    Am J Hum Genet; 2013 Jan; 92(1):76-80. PubMed ID: 23246288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphatase and tensin homolog immunohistochemical staining and clinical criteria for Cowden syndrome in patients with trichilemmoma or associated lesions.
    Jin M; Hampel H; Pilarski R; Zhou X; Peters S; Frankel WL
    Am J Dermatopathol; 2013 Aug; 35(6):637-40. PubMed ID: 23715080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTEN hamartoma tumour syndrome: case report based on data from the Iranian hereditary colorectal cancer registry and literature review.
    Rahmatinejad Z; Goshayeshi L; Bergquist R; Goshayeshi L; Golabpour A; Hoseini B
    Diagn Pathol; 2023 Apr; 18(1):43. PubMed ID: 37016356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic and Therapeutic Targeting of PTEN Loss in Bone Malignancies.
    Xi Y; Chen Y
    J Cell Biochem; 2015 Sep; 116(9):1837-47. PubMed ID: 25773992
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.